Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $6.25.

Several analysts have recently weighed in on HUMA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. HC Wainwright raised their price target on shares of Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. BTIG Research reaffirmed a “buy” rating and set a $2.00 price objective on shares of Humacyte in a report on Tuesday, June 16th. Finally, Wall Street Zen lowered Humacyte from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th.

Insider Buying and Selling

In related news, Director Kathleen Sebelius purchased 56,818 shares of the stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the completion of the transaction, the director directly owned 148,025 shares of the company’s stock, valued at approximately $130,262. The trade was a 62.30% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shamik J. Parikh sold 45,887 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the transaction, the insider owned 272,713 shares of the company’s stock, valued at $245,441.70. This represents a 14.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sei Investments Co. bought a new stake in shares of Humacyte in the 1st quarter worth about $56,000. R Squared Ltd boosted its position in Humacyte by 140.5% in the first quarter. R Squared Ltd now owns 62,911 shares of the company’s stock valued at $38,000 after buying an additional 36,758 shares in the last quarter. Private Advisor Group LLC grew its stake in Humacyte by 48.3% during the first quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock worth $505,000 after buying an additional 271,222 shares during the last quarter. Wealth Effects LLC grew its stake in Humacyte by 33.6% during the first quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock worth $124,000 after buying an additional 51,433 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Humacyte by 841.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock worth $68,000 after buying an additional 62,931 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Stock Down 3.2%

Shares of HUMA stock opened at $0.66 on Friday. Humacyte has a one year low of $0.55 and a one year high of $2.84. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The stock has a fifty day moving average price of $0.97 and a 200 day moving average price of $0.96. The stock has a market cap of $146.44 million, a P/E ratio of -1.16 and a beta of 2.52.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The firm had revenue of $0.49 million for the quarter, compared to analyst estimates of $1.46 million. Analysts predict that Humacyte will post -0.34 earnings per share for the current year.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.